Franziska has been working in life science for almost 20 years. Throughout her career she has focused on working for and with innovative pharma and biotech players as well as CDMOs, supporting them in bringing innovation to patients faster and thus moving towards the Future of Health. She joined Arthur D. Little in 2020, where she leads the Healthcare and Life Science practice. In her recent work she has been supporting clients in successfully adopting and managing technological disruptions such as e.g. mRNA therapies or proteomics, but also in implementing and scaling use of data in drug development.

Prior to joining Arthur D. Little, Franziska worked at Boehringer Ingelheim from 2005 to 2016 leading teams focused on end-to-end innovation and development of biologics, with focus on integrated, fast-to-market approaches. She has also previously supported pharma and biotech clients at McKinsey and PA Consulting.

Franziska holds a Ph.D. in biochemistry from ETH Zurich and has been doing research at Harvard Medical School/Dana Farber Cancer Institute, Rockefeller University and the RIKEN Institute.